Type 2 Diabetes Treatment
8 articles on Type 2 Diabetes Treatment, written by Shotlee and medically reviewed for clinical accuracy.
MSN Labs Launches Semabest: Generic Semaglutide in India
MSN Laboratories has launched Semabest, its affordable generic version of semaglutide, in the Indian market after CDSCO approval. Priced nearly 50% lower than the branded drug and available in pre-filled pens, it promises comparable efficacy in HbA1c reduction, glucose control, and weight loss. This move aims to address India's diabetes crisis affecting 90 million people.
5 min read
Hidden Reason Ozempic Fails for Some: GLP-1 Resistance Revealed
New research reveals a hidden genetic reason why Ozempic fails for some: GLP-1 resistance linked to PAM gene variants affecting 10% of the population. Despite higher GLP-1 levels, these individuals show reduced drug efficacy in lowering blood sugar. Discover the study's findings from humans, mice, and clinical trials.
7 min read
What Is Orforglipron? New Oral Weight-Loss Pill Trial Results
A groundbreaking phase 3 trial shows orforglipron, a new daily oral weight-loss pill, surpassing oral semaglutide in blood sugar control and weight reduction for type 2 diabetes patients. This small-molecule GLP-1 agonist offers advantages over injectables like Ozempic by eliminating needles and refrigeration needs. However, higher gastrointestinal side effects raise questions about long-term tolerability.
5 min read
Sun Pharma, Dr Reddy's, Glenmark Launch Generic Semaglutide in India
Indian pharma leaders Sun Pharma, Dr Reddy's, and Glenmark have launched generic semaglutide injections in India, slashing costs compared to Ozempic and Wegovy after patent expiry. With weekly prices starting at Rs 325, these options make GLP-1 therapy accessible for type 2 diabetes and weight management. Zydus joins with more affordable brands, transforming treatment affordability.
5 min read
How Gila Monster Venom Led Scientists to Ozempic
A venomous desert lizard, the Gila monster, holds a surprising key to one of medicine's biggest breakthroughs: Ozempic. Its venom revealed exendin-4, a stable GLP-1 mimic that paved the way for transformative diabetes therapies. This unlikely origin story highlights nature's role in modern metabolic health.
5 min read
India GLP-1 Weight-Loss Drug Market to Reach ₹5,000 Crore by 2030: CareEdge
India's GLP-1 and weight-loss drug market is set for explosive growth, expanding fivefold to ₹5,000 crore by 2030, according to CareEdge Ratings. Semaglutide's patent expiry will trigger sharp price cuts, boosting access amid surging demand from type 2 diabetes patients. However, generic makers face patent battles, manufacturing hurdles, and safety scrutiny.
5 min read
Abbott Partners with Novo for Semaglutide Extensior in India
Abbott has tied up with Novo Nordisk India to commercialize Extensior, the second brand of semaglutide injection following Ozempic's launch. This move positions Abbott as the second firm with sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma. With demand surging and generics on the horizon, here's what it means for patients.
4 min read
GLP-1 Drugs & Hair Loss: New Study Reveals Potential Risk
Emerging research is spotlighting a potential link between popular GLP-1 medications like Ozempic and Wegovy and hair loss conditions such as telogen effluvium and androgenetic alopecia. A study of nearly 550,000 patients found a significant association after 12 months of use, even after adjusting for key factors. While benefits for diabetes and weight loss remain strong, awareness and monitoring are crucial.
6 min read